Cocrystal Pharma, Inc. (NASDAQ: COCP) Investor Securities Class Action Lawsuit 09/20/2018

If you purchased a significant amount of shares of Cocrystal Pharma, Inc. (NASDAQ: COCP) between September 23, 2013 through September 7, 2018 , and / or if you purchased any NASDAQ: COCP shares prior to September 23, 2013 through September 7, 2018 and continue to hold any of those shares, you have certain options and for certain investors are short and strict deadlines running. Deadline: November 19, 2018. NASDAQ: COCP investors should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Cocrystal Pharma
Case Name: 
Cocrystal Pharma Shareholder Class Action Lawsuit 09/20/2018
Case Status: 
Lawsuit Filed
Affected Securities
NASDAQ: COCP
Lawsuit Overview
Type of Lawsuit: 
Shareholder Class Action
Date Filed: 
09/20/2018
Class Period Begin: 
09/23/2013
Class Period End: 
09/07/2018
Court of Filing: 
U.S. District Court for the District of New Jersey
Deadline To File for Lead: 
11/19/2018
Summary: 

An investor in shares of Cocrystal Pharma, Inc. (NASDAQ: COCP) filed a lawsuit in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by Cocrystal Pharma, Inc. in connection with certain allegedly false and misleading statements made between September 23, 2013 through September 7, 2018.

Cocrystal Pharma, Inc, formerly BioZone Pharmaceuticals, Inc,is a clinical stage biotechnology company that engages in discovering and developing various novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses.

On September 7, 2018, the U.S. Securities and Exchange Commission (“SEC”) filed a lawsuit against former officers of BioZone Pharmaceuticals, Inc as well as other individuals and corporations, alleging violations of the federal securities laws. The SEC complaint alleges that defendants were participants in “highly profitable ‘pump-and-dump’ schemes . . . from 2013 through 2018” in the stock of three public companies, including BioZone, that, “while enriching Defendants by millions of dollars, left retail investors holding virtually worthless shares.”

According to the complaint the plaintiff alleges on behalf of purchasers of Cocrystal Pharma, Inc. (NASDAQ: COCP) common shares between September 23, 2013 through September 7, 2018, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between September 23, 2013 through September 7, 2018, the defendants made false and/or misleading statements and/or failed to disclose that the defendants were engaged in a pump-and-dump scheme to artificially inflate Cocrystal’s stock price, that this illicit scheme would result in governmental scrutiny, including from the SEC, that defendants failed to abide by SEC disclosure regulations, and that as a result, defendants’ statements about Cocrystal’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.